Evidence map›Paper›PMID 42009784›Full record

ArticleScientific reports2026

Biophysical and aerodynamic properties of a peptide targeting the A-kinase anchoring function of PI3Kγ for pulmonary cAMP modulation.

Angela Della Sala, Valentina Sala, Cosmin Stefan Butnarasu, Laura Tasca, Gabriella Costabile, Marco Mergiotti, Andrea Gramegna, Francesco Blasi, Stefano Aliberti, Francesca Ungaro and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Angela Della Sala *Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Torino, Via Nizza 52, Turin, 10126, Italy.
Valentina Sala *Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Torino, Via Nizza 52, Turin, 10126, Italy.
Cosmin Stefan ButnarasuDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Torino, Via Nizza 52, Turin, 10126, Italy.
Laura TascaDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Torino, Via Nizza 52, Turin, 10126, Italy.
Gabriella CostabileDepartment of Pharmacy, Federico II University, Naples, Italy.
Marco MergiottiDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Torino, Via Nizza 52, Turin, 10126, Italy.
Andrea GramegnaInternal Medicine Department, Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, 20122, Italy.
Francesco BlasiInternal Medicine Department, Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, 20122, Italy.
Stefano AlibertiDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan, 20072, Italy.
Francesca UngaroDepartment of Pharmacy, Federico II University, Naples, Italy.
Sonja VisentinDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Torino, Via Nizza 52, Turin, 10126, Italy.
Emilio HirschDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Torino, Via Nizza 52, Turin, 10126, Italy.
Alessandra GhigoDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Torino, Via Nizza 52, Turin, 10126, Italy. alessandra.ghigo@unito.it.

Funding

Fondazione Cariplo #2018-0498Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Regione Lombardia Cystic Fibrosis Funding 2022 Cod. 18563 Capitolo 13.01.1PRIN 2022 2022WHSCL3Research Grant Ministero della Salute RC 2023/260-01Roche Foundation Bando Roche per la Ricerca 2019Telethon Foundation GGP20079
6 · The paper itself

Abstract

Cyclic AMP (cAMP) signaling specificity relies on precise spatial regulation mediated by A-kinase anchoring proteins (AKAPs), which localize protein kinase A (PKA) within defined microdomains. Dysregulated AKAP signaling contributes to different pathologies, including chronic inflammatory airway diseases, making AKAP disruptors attractive therapeutic candidates. We previously showed that a cell-permeable PI3Kγ mimetic peptide (PI3Kγ MP, also known as KIT2014) that disrupts the interaction between the AKAP PI3Kγ and PKA enhances β₂-adrenergic receptordriven cAMP signaling to promote airway relaxation, mucus clearance, and reduced inflammation. Here, we investigated the structural, biophysical, and aerodynamic properties of PI3Kγ MP to gain deeper mechanistic insight. The peptide adopted a partially structured conformation essential for PKA binding, assembled into dynamic nanoparticles compatible with epithelial and mucus penetration, and retained biological activity in protease-rich environments, such as cystic fibrosis sputum. Aerodynamic profiling further demonstrated mass median aerodynamic diameters suitable for deep lung deposition upon nebulization. Collectively, these results position PI3Kγ MP as a first-in-class disruptor of the PI3Kγ-PKA complex with strong translational potential as an inhaled therapy for obstructive airway diseases driven by cAMP dysregulation.

Indexed as

A Kinase Anchor ProteinsClass Ib Phosphatidylinositol 3-KinaseCyclic AMPCyclic AMP-Dependent Protein KinasesLungPeptidesAnimalsHumansProtein BindingSignal TransductionA Kinase Anchor ProteinsClass Ib Phosphatidylinositol 3-KinaseCyclic AMPCyclic AMP-Dependent Protein KinasesPeptidesAKAPcAMPInhaled therapyMimetic peptideObstructive airway diseasesPI3Kγ

Identifiers

PMID42009784
PMCPMC13260995

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.